Sotrovimab is recommended for adults and paediatric patients (over 12 years) diagnosed with obesity, who have moderate COVID-19 infection. Immunocompromised patient who have various comorbidities and are at a higher risk of progressing towards severe COVID infection. People with neurological disorders who are prone to complex COVID infection. Unvaccinated people. Older people above 65 years of age. Pregnant women are also eligible to use this treatment.